Immunex Enbrel
Executive Summary
Supplemental application for etanercept filed Nov. 25 for use in moderately to severely active polyarticuar course juvenile rheumatoid arthritis. FDA has indicated that the indication, if approved, will be granted orphan drug exclusivity